Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Rectal Cancer, Version 6.2020 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hoffe, S., Hubbard, J., Hunt, S., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Johnson-Chilla, A., Gurski, L. A. 2020; 18 (7): 807–15

Abstract

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E- or HER2 amplification-positive disease.

View details for DOI 10.6004/jnccn.2020.0032

View details for Web of Science ID 000577820100003

View details for PubMedID 32634771